Rituximab treatment of cyclophosphamide-resistant patients with ANCA-associated vasculitis
Not Applicable
- Conditions
- ANCA-associated vasculitis
- Registration Number
- JPRN-UMIN000000906
- Lead Sponsor
- Research Comittee of Intractable Vasculitis Syndrome of the Ministry of Health, Labor and Welfare of Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. severe infection (including tuberculosis, HCV, HBV and HIV). 2. history of hypersensitivity to mouse-derived protein 3. congestive heart failure with NYHA III or IV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complete remission at 12 months
- Secondary Outcome Measures
Name Time Method adverse events, BVAS/WG, VDI